drugset
Drugs / mutant prourokinase
last change Jul 2023 re-read 9 days ago

mutant prourokinase

also known as M-pro-urokinase · m-proUK
Developed for
ischemic stroke
Investigated by
DUMAS is sponsored by an unrestricted grant from Thrombolytic Science International, paid to the institution. · Erasmus Medical Center

Trials 1

today NCT04256473 · Ph 2
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04256473 Aug 2019 → Mar 2022 ischemic stroke Erasmus Medical Center Completed Missed primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as mutant prourokinase “Safety and Efficacy of Dual Thrombolytic Therapy With Mutant Prourokinase and Small Bolus Alteplase for Ischemic Stroke: A Randomized Clinical Trial.” PMID 37213122 ↗ Jul 2023
1

NCT04256473 ↗
Known as M-pro-urokinase “Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke” NCT04256473 ↗
Known as m-proUK “Mutant pro-urokinase (m-proUK) does not deplete fibrinogen and lyses fibrin only after induction with alteplase.” PMID 35945566 ↗ Aug 2022